The Benin is on the brink of a historic milestone in healthcare, as its regulatory agency undergoes a rigorous evaluation to secure the World Health Organization’s (WHO) Maturity Level 3 (ML3) certification. This prestigious recognition, expected to be announced in July 2026, would place Benin among the top performers in pharmaceutical regulation across West Africa.
An intensive WHO assessment unlocks new healthcare potential
From July 6 to 9, 2026, a high-level delegation of eight WHO experts conducted an exhaustive audit of the Agence Béninoise du Médicament et des autres produits de Santé (ABMed). The inspection scrutinized every aspect of the agency’s operations, including drug approval processes, market surveillance, pharmacovigilance, and clinical trials.
The evaluation aimed to verify Benin’s compliance with the most stringent international standards, ensuring that its pharmaceutical system meets global benchmarks for safety, efficacy, and quality. Preliminary findings, shared with key stakeholders in Cotonou, highlight significant progress, reinforcing the country’s commitment to eradicating substandard and falsified medicines.
What the WHO’s ML3 certification means for Benin
Achieving ML3 is far more than a regulatory badge—it is a testament to Benin’s transformation into a robust and self-sufficient healthcare system. The certification confirms that the country’s pharmaceutical governance is now fully capable of independently overseeing the entire supply chain, from production to distribution.
For the people of Benin, this means greater access to safe, high-quality medications. The certification also opens doors to stronger international partnerships, boosts local pharmaceutical production, and enhances the country’s credibility in regional trade. Most importantly, it sends a clear message: Benin is taking decisive action against the scourge of counterfeit drugs, protecting its citizens from life-threatening health risks.
A decade of reforms culminating in global recognition
The journey to this pivotal moment began in 2017, when the Benin government initiated sweeping reforms in its pharmaceutical sector. The restructuring of the former pharmacy directorate into the autonomous ABMed, coupled with stricter legislative frameworks, laid the groundwork for this achievement. In July 2026, the Minister of Health, Professor Benjamin Hounkpatin, reaffirmed the state’s unwavering commitment to supporting ABMed in securing this certification.
Professor Hounkpatin emphasized that this milestone is not merely a governmental success but a collective triumph for healthcare professionals, policymakers, and the public. The reforms have not only modernized the regulatory landscape but have also fostered a culture of accountability and excellence within the health sector.
Benin’s rise as a healthcare leader in francophone West Africa
If the final assessment confirms the transition to ML3, Benin will stand as the second francophone nation in West Africa to achieve this status, following in the footsteps of Senegal. This accomplishment positions Benin as a model for pharmaceutical governance in the region, demonstrating that strategic investments and political will can align national systems with global best practices.
The implications are far-reaching: improved regional collaboration, enhanced drug manufacturing capabilities, and a strengthened healthcare framework that prioritizes patient safety. For Benin, this is not just a regulatory victory—it is a leap toward self-reliance and international credibility in healthcare.
Final steps toward a new healthcare era
The WHO mission in July 2026 marks a turning point for Benin’s public health trajectory. While the preliminary results are promising, the final certification hinges on the implementation of the remaining recommendations. By inching closer to ML3, Benin proves that patient safety and pharmaceutical sovereignty are no longer distant goals but an imminent reality.
The country now stands at the threshold of a new healthcare paradigm—one where innovation, regulation, and public trust converge to deliver unparalleled health outcomes for its citizens.